Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BGB-16673 with Phenytoin or Itraconazole in Healthy Participants
NCT06906809Phase 1Completed
- Sponsor
- BeiGene
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of catadegbrutinib (2 arms), sponsored by BeiGene. Primary endpoints: Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity at Day 20, Area Under the Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration at Day 20 and 1 more. Started Apr 2025; status: completed.
02
Drugs
catadegbrutinib
Beyond the preview
Go deeper on NCT06906809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06906809.